Compare Heron Therapeutics Inc (HRTX) vs Materials Select Sector SPDR Fund (XLB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Heron Therapeutics Inc vs Materials Select Sector SPDR Fund — how do they compare? Heron Therapeutics Inc trades at $0.33 (market cap $61.47M), while Materials Select Sector SPDR Fund trades at $52.79. The key difference: Materials Select Sector SPDR Fund is trading nearer its 52-week high, Heron Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| HRTX | XLB | |
|---|---|---|
Market Cap | $61.47M | — |
Sector | Health | — |
52-Week High | $1.49 | $53.62 |
52-Week Low | $0.32 | $42.23 |
Enterprise Value | $168.21M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.3152, down 4.54% today, amid bearish technical signals and mixed earnings. The stock shows a high gross margin of 70.07% but negative net income margins, with Q2 2026 missing revenue and EPS estimates. Recent news highlights patent litigation developments and quarterly results falling short of expectations, contributing to investor caution.
The outlook remains challenged by persistent losses and operational cash burn, though analyst consensus is strongly bullish with 94.74% buy ratings. Key risks include execution on product sales, competitive pressures, and reliance on financing activities to sustain operations amid negative profitability.
XLB trades at $53.14, showing minimal daily movement with a slight decline of 0.08%. Technical indicators signal a bullish trend with strong moving average support and oscillators showing mixed signals. The materials sector ETF benefits from infrastructure spending and AI-related demand, though recent articles suggest the cyclical recovery may be largely priced in. Dividend payments are scheduled for 2026.
The outlook for XLB remains positive due to sector tailwinds from infrastructure and manufacturing trends, though valuation concerns exist after recent gains. Key risks include cyclical sector exposure and potential overvaluation. Analyst sentiment appears cautiously optimistic with technical strength supporting near-term momentum.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Heron Therapeutics Inc
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →About Materials Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: chemicals; metals and mining; paper and forest products; containers and packaging; and construction materials. The fund is non-diversified.
Read more on XLB →
